MS_Money_Moves

MS_Money_Moves

Trade Summary Ticker: CCXI (Last: $8.84) Entry: $8.50-8.84 Price Target: $13-15.0+ Target Timeframe: 0-6 weeks Trade Thesis CCXI is an orphan/rare disease-focused company with a robust pipeline of clinical assets targeting autoimmune and inflammatory disorders as well as cancer. The company's lead asset CCX168 (Avacopan) is an orally administered small...

MS_Money_Moves

NGM I remain bullish on NGM's near-term price performance. Seventy-one percent of the outstanding shares are held by insiders and institutions. The largest shareholders being The Column Group L.P, David Goeddel (managing partner at The Column Group), and Peter Svennilson who are lauded in the biopharma industry. Goeddel's last company (Tularik) was sold to Amgen...

MS_Money_Moves

OCUL OCUL has a pattern of descending triangles over the past 4-months (July-November 2019). The company launched its second commercial product Dextenza in the 2nd quarter where it gave away free samples. Its other product 'ReSure Sealent' has posted weak sales numbers ($472K in 1Q19 and ~600K in 2Q19). Dextenza is priced at $850 and is essentially an...

MS_Money_Moves

MRKR Entered MRKR at $4.01 on Friday (11/1/19) and am monitoring for a sustained trend reversal. Watching for SP to bounce off $4.10, or if that does not hold, $4.01. If it does not reverse here I think it'll consolidate between $3.83 and $4.32. A reversal would coincide with a run-up into Q3 earnings which should be sometime this month and phase 2 data in...

MS_Money_Moves

I exited NGM for a 26% gain yesterday and re-entered today at $12.80. The stock appears to found a new channel following the release of interim phase 2 NASH data. This trade involves chart patterns and fundamentals. NGM is backed by Column Group L.P and Merck (MRK). Their data was positive. The float is very low and locked up by the above NGM shareholders. Should...

MS_Money_Moves

RGNX sold off 12% today on news of a partial clinical hold on an NVS gene therapy trial using its vector. After reading the press release I think this was an overreaction and the stock price will bounce back swiftly into RGNX earnings catalyst on 11/08/2019. It is sold off right to the bottom of its channel making for a beautiful setup!

MS_Money_Moves

Looking for a bounce on EYPT.